Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
:::

李重賓 (Chung-Pin Li)

[簡介]

  • 學歷
    • Post-doc fellow, Division of GI/Liver Pathology, Department of Pathology, Johns Hopkins University School of Medicine,
    • Ph.D., Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University,
    • M.D., School of Medicine, College of Medicine, National Yang Ming Chiao Tung University,
  • 經歷
    現職:
    • - Now, Director, Division of Clinical Skills Training, Department of Medical Education, Taipei Veterans General Hospital,
    • - Now, Attending Physician, Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital,
    • - Now, Professor, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University,
    經歷:
    • - , Director, Gastroenterology and Hepatology Ward, Department of Medicine, Taipei Veterans General Hospital,
    • - , Deputy Convener, Cholangiocarcinoma Multi-specialty Team, Taipei Veterans General Hospital,
    • - , Deputy Executive Secretary, Human Research Protection Center, Taipei Veterans General Hospital,
    • - , Member and Deputy Executive Secretary, IRB, Taipei Veterans General Hospital,
    • - , Executive Editor, Journal of Chinese Medical Association,
    • - , Associate Editor, Clinical Medicine,
  • 醫療專長
    1. Medical treatment of pancreatic cancer
    2. Medical treatment of digestive system cancer
    3. Treatment of chronic hepatitis B and C
    4. Treatment of liver cirrhosis and its complications
    5. Diagnosis and treatment of abdominal ultrasound and digestive tract endoscopy
    6. Clinical skills training
    7. Medical education

[著作]

  1. Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Randomized Phase 3 Trial of Pegvorhyaluronidase Alfa (PEGPH20) With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020 Sep 20;38(27):3185-3194.
  2. Li CP, Chia-Chi Chen, Li-Li Chen, Yu-Ting Hsu, Shih-Sheng Jiang, Chi-Shuan Fan, Kee Voon Chua, Sheng-Xiang Huang, Yi-Ming Shyr, Li-Tzong Chen & Tze-Sing Huang. Myeloid-Derived Macrophages and Secreted HSP90α Induce Pancreatic Ductal Adenocarcinoma Development. Oncoimmunology 2018 Jan. 9; 7(5), e1424612.
  3. Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, Li CP* (correspondent). What constitutes normal hemoglobin concentrations among community-dwelling older adults? Journal of the American Geriatrics Society 2016 Jun;64(6):1233-41.
  4. Wang JP, Wu CY, Hwang IH, Kao CH, Hung YP, Hwang SJ, Li CP* (correspondent). How different is the care of terminal pancreatic cancer patients in inpatient palliative care units and acute hospital wards? A nationwide population-based study. BMC Palliative Care 2016 Jan 8;15(1):1.
  5. Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP* (correspondent), Chao Y. A Phase II Study of Sequential Capecitabine plus Oxaliplatin Followed by Docetaxel plus Capecitabine in Patients with Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial. Medicine 2016 Jan;95(3):e2565.
  6. Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, MS Lee, Li CP* (correspondent). High Serum Uric Acid Levels Are Associated with All-Cause and Cardiovascular, but Not Cancer, Mortality in Elderly Adults. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY 2015 Sep;63(9):1829-36.
  7. Wu CY, Chang WP, Chang YH, Li CP* (correspondent), Chuang CM. The risk of irritable bowel syndrome in patients with endometriosis during a 5-year follow-up: a nationwide population-based cohort study. International Journal of Colorectal Disease 2015 Jul;30(7):907-12.
  8. Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY, Hung YP, Chen MH, Lee WP, Luo JC, Chao Y, Li CP* (correspondent). Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget 2015 Jul 20;6(20):18162-73.
  9. Wang JP, Kao FY, Wu CY, Hung YP, Chao Y, Chou YJ, Li CP* (correspondent). Nucleos(t)ide analogs associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study. Cancer 2015 May 1;121(9):1446-55.
回到最上